{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:03:08Z","timestamp":1787065388494,"version":"build-2736575974"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03208-z","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T10:18:35Z","timestamp":1766744315000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Emerging Anti-Cancer and Repurposed Therapies for Overcoming Multidrug Resistance in Lung Cancer"],"prefix":"10.1007","volume":"43","author":[{"given":"Nilay","family":"Solanki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratham","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sargam","family":"Kewalramani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umang","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swayamprakash","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"3208_CR1","volume-title":"Cancer fact sheet","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Cancer fact sheet. Geneva: WHO; 2022."},{"key":"3208_CR2","volume-title":"Lung cancer statistics","author":"American Cancer Society","year":"2023","unstructured":"American Cancer Society. Lung cancer statistics. Atlanta: ACS; 2023."},{"issue":"7","key":"3208_CR3","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","volume":"18","author":"RW Robey","year":"2018","unstructured":"Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018;18(7):452\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"14 Suppl","key":"3208_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1158\/1538-7445.AM2016-251","volume":"76","author":"B Pal","year":"2016","unstructured":"Pal B, Bayat-Mokhtari R, Li H, Bhuyan R, Talukdar J, Sandhya S, et al. Stem cell altruism May serve as a novel drug resistance mechanism in oral cancer. Cancer Res. 2016;76(14 Suppl):251.","journal-title":"Cancer Res"},{"issue":"3","key":"3208_CR5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.15171\/apb.2017.041","volume":"7","author":"B Mansoori","year":"2017","unstructured":"Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull. 2017;7(3):339\u201348.","journal-title":"Adv Pharm Bull"},{"issue":"4","key":"3208_CR6","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1073\/pnas.78.4.2110","volume":"78","author":"LR Beach","year":"1981","unstructured":"Beach LR, Palmiter RD. Amplification of the metallothionein-I gene in cadmium-resistant mouse cells. Proc Natl Acad Sci U S A. 1981;78(4):2110\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"3208_CR7","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.molcel.2013.02.013","volume":"49","author":"JA Simon","year":"2013","unstructured":"Simon JA, Kingston RE. Occupying chromatin: polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put. Mol Cell. 2013;49(5):808\u201324.","journal-title":"Mol Cell"},{"issue":"3","key":"3208_CR8","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/cancers6031769","volume":"6","author":"G Housman","year":"2014","unstructured":"Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. Drug resistance in cancer: an overview. Cancers (Basel). 2014;6(3):1769\u201392.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"3208_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.blre.2005.08.003","volume":"20","author":"ZW Li","year":"2006","unstructured":"Li ZW, Dalton WS. Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev. 2006;20(6):333\u201342.","journal-title":"Blood Rev"},{"issue":"10","key":"3208_CR10","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714\u201326.","journal-title":"Nat Rev Cancer"},{"key":"3208_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-1-4939-3347-1_2","volume-title":"Cancer drug resistance: methods in molecular biology","author":"BC Baguley","year":"2016","unstructured":"Baguley BC. Classical and targeted anticancer drugs: an appraisal of mechanisms of multidrug resistance. In: Rueff J, Rodrigues A, editors. Cancer drug resistance: methods in molecular biology. New York: Humana; 2016. pp. 19\u201337."},{"issue":"7586","key":"3208_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nature16863","volume":"529","author":"J Settleman","year":"2016","unstructured":"Settleman J. Cancer: bet on drug resistance. Nature. 2016;529(7586):289\u201390.","journal-title":"Nature"},{"issue":"1","key":"3208_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/00001813-199102000-00002","volume":"2","author":"SE Benner","year":"1991","unstructured":"Benner SE, Wahl GM, Von Hoff DD. Double minute chromosomes and homogeneously staining regions in tumors taken directly from patients versus in human tumor cell lines. Anticancer Drugs. 1991;2(1):11\u201325.","journal-title":"Anticancer Drugs"},{"issue":"6","key":"3208_CR14","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","volume":"155","author":"VK Arora","year":"2013","unstructured":"Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013;155(6):1309\u201322.","journal-title":"Cell"},{"issue":"4","key":"3208_CR15","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.cell.2011.07.026","volume":"146","author":"PB Gupta","year":"2011","unstructured":"Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell. 2011;146(4):633\u201344.","journal-title":"Cell"},{"issue":"6166","key":"3208_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1126\/science.1241328","volume":"343","author":"DA Nathanson","year":"2014","unstructured":"Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 2014;343(6166):72\u20136.","journal-title":"Science"},{"issue":"8","key":"3208_CR17","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/nrc2892","volume":"10","author":"RA Gatenby","year":"2010","unstructured":"Gatenby RA, Gillies RJ, Brown JS. The evolutionary dynamics of cancer prevention. Nat Rev Cancer. 2010;10(8):526\u20137.","journal-title":"Nat Rev Cancer"},{"issue":"7467","key":"3208_CR18","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12626","volume":"501","author":"MR Junttila","year":"2013","unstructured":"Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501(7467):346\u201354.","journal-title":"Nature"},{"key":"3208_CR19","volume-title":"Mechanisms of drug resistance in neoplastic cells: Bristol-Myers cancer symposia","author":"PV Woolley","year":"2013","unstructured":"Woolley PV, Tew KD. Mechanisms of drug resistance in neoplastic cells: Bristol-Myers cancer symposia. New York: Academic; 2013."},{"issue":"6","key":"3208_CR20","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1515\/bmc-2013-0026","volume":"4","author":"A Matsui","year":"2013","unstructured":"Matsui A, Ihara T, Suda H, Mikami H, Semba K. Gene amplification: mechanisms and involvement in cancer. Biomol Concepts. 2013;4(6):567\u201382.","journal-title":"Biomol Concepts"},{"key":"3208_CR21","unstructured":"BioNTech SE. BioNTech announces positive topline phase 2 results for mRNA immunotherapy candidate BNT111 in patients with advanced melanoma. 2024 Jul 30. https:\/\/investors.biontech.de\/news-releases\/news-release-details\/biontech-announces-positive-topline-phase-2-results-mrna"},{"key":"3208_CR22","unstructured":"BioNTech SE. BioNTech BNT116 lung cancer mRNA vaccine clinical trials initiated. 2024 Aug 25. https:\/\/www.globenewswire.com\/news-release\/2024\/08\/25\/2935195\/0\/en\/BioNTech-BNT116-Lung-Cancer-mRNA-Vaccine-Clinical-Trials-Initiated.html"},{"key":"3208_CR23","unstructured":"Akeso Inc. Ivonescimab in combination with chemotherapy demonstrates statistically significant and strongly positive results in first-line treatment of Sq-NSCLC vs. tislelizumab in combination with chemotherapy. 2025 Apr 23."},{"key":"3208_CR24","unstructured":"Nuvalent Inc. Updated data for Nuvalent\u2019s ALK-selective inhibitor, NVL-655, and ROS1-selective inhibitor, Zidesamtinib. 2024 Sep 9."},{"key":"3208_CR25","unstructured":"BeyondSpring P. Subgroup analysis of non-squamous EGFR WT NSCLC patients from the global phase 3 trial DUBLIN-3. 2022 Oct 21."},{"key":"3208_CR26","unstructured":"CStone Pharmaceuticals. CStone announces China\u2019s NMPA acceptance of NDA for sugemalimab in stage III NSCLC. 2021 Sep 2. https:\/\/www.cstonepharma.com\/en\/html\/news\/2812.html"},{"key":"3208_CR27","unstructured":"Dizal Pharma. Dizal submits new drug application to US FDA for Sunvozertinib in NSCLC. 2024."},{"key":"3208_CR28","unstructured":"Bristol Myers Squibb. FDA approves Augtyro (repotrectinib) for NTRK-positive solid tumors. 2024. https:\/\/shorturl.at\/y5z3u"},{"key":"3208_CR29","unstructured":"AstraZeneca. Datopotamab deruxtecan BLA accepted in US for advanced non-squamous NSCLC. 2024. https:\/\/shorturl.at\/j4Tri"},{"key":"3208_CR30","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.278","author":"S Park","year":"2020","unstructured":"Park S, Ku BM, Jung HA, Sun JM, Ahn JS, Lee SH, et al. EGFR C797S as a resistance mechanism of lazertinib in non-small cell lung cancer with EGFR T790M mutation. Cancer Res Treat. 2020. https:\/\/doi.org\/10.4143\/crt.2020.278","journal-title":"Cancer Res Treat"},{"issue":"9","key":"3208_CR31","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121(9):725\u201337.","journal-title":"Br J Cancer"},{"key":"3208_CR32","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.2147\/OTT.S249652","volume":"13","author":"Z Xiao","year":"2020","unstructured":"Xiao Z, Huang X, Xie B, Xie W, Huang M, Lin L. Primary resistance to brigatinib in a patient with lung adenocarcinoma harboring ALK G1202R mutation and LIPI-NTRK1 rearrangement. Onco Targets Ther. 2020;13:4591\u20135.","journal-title":"Onco Targets Ther"},{"issue":"Suppl 4","key":"3208_CR33","doi-asserted-by":"publisher","first-page":"S378","DOI":"10.21037\/tlcr.2019.04.15","volume":"8","author":"B Ricciuti","year":"2019","unstructured":"Ricciuti B, Lamberti G, Roila F, Metro G. Brigatinib for ALK-TKI na\u00efve ALK-positive advanced non-small cell lung cancer: an effective but still broken option. Transl Lung Cancer Res. 2019;8(Suppl 4):S378.","journal-title":"Transl Lung Cancer Res"},{"issue":"5","key":"3208_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijo.2021.5270","volume":"59","author":"J He","year":"2021","unstructured":"He J, Huang Z, Han L, Gong Y, Xie C. Mechanisms and management of 3rd generation EGFR TKI resistance in advanced non-small cell lung cancer. Int J Oncol. 2021;59(5):1\u201320.","journal-title":"Int J Oncol"},{"key":"3208_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.787585","volume":"11","author":"JB Blaquier","year":"2021","unstructured":"Blaquier JB, Cardona AF, Recondo G. Resistance to KRASG12C inhibitors in non-small cell lung cancer. Front Oncol. 2021;11:787585.","journal-title":"Front Oncol"},{"issue":"1","key":"3208_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00328-x","volume":"6","author":"DA Farnsworth","year":"2022","unstructured":"Farnsworth DA, Inoue Y, Johnson FD, de Rappard-Yuswack G, Lu D, Shi R, et al. MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression. NPJ Precis Oncol. 2022;6(1):88.","journal-title":"NPJ Precis Oncol"},{"key":"3208_CR37","unstructured":"Verastem Oncology. Verastem Oncology outlines 2025 strategic priorities. 2025. Available from: https:\/\/investor.verastem.com\/news-releases\/news-release-details\/verastem-oncology-outlines-2025-strategic-priorities-and"},{"key":"3208_CR38","doi-asserted-by":"publisher","first-page":"1562167","DOI":"10.3389\/fphar.2025.1562167","volume":"16","author":"Q Ye","year":"2025","unstructured":"Ye Q, Zhuang XZ, Li J, Zhou X. Targeting the inhibitors of apoptosis proteins (IAPs) to combat drug resistance in cancers. Front Pharmacol. 2025;16:1562167.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3208_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01808-1","volume":"9","author":"Y Xia","year":"2024","unstructured":"Xia Y, Sun M, Huang H, Jin WL. Drug repurposing for cancer therapy. Signal Transduct Target Ther. 2024;9(1):92.","journal-title":"Signal Transduct Target Ther"},{"key":"3208_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.741326","volume":"11","author":"AS Jain","year":"2021","unstructured":"Jain AS, Prasad A, Pradeep S, Dharmashekar C, Achar RR, Silina E, et al. Everything old is new again: drug repurposing approach for non-small cell lung cancer targeting MAPK signaling pathway. Front Oncol. 2021;11:741326.","journal-title":"Front Oncol"},{"issue":"6","key":"3208_CR41","doi-asserted-by":"publisher","first-page":"e0233112","DOI":"10.1371\/journal.pone.0233112","volume":"15","author":"B Li","year":"2020","unstructured":"Li B, Dai C, Wang L, Deng H, Li Y, Guan Z, et al. A novel drug repurposing approach for non-small cell lung cancer using deep learning. PLoS One. 2020;15(6):e0233112.","journal-title":"PLoS One"},{"key":"3208_CR42","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1038\/srep03120","volume":"3","author":"Y Zhao","year":"2013","unstructured":"Zhao Y, Lu H, Yan A, Yang Y, Meng Q, Sun L. ABCC3 as a marker for multidrug resistance in non-small cell lung cancer. Sci Rep. 2013;3:3120.","journal-title":"Sci Rep"},{"issue":"2","key":"3208_CR43","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.lungcan.2005.06.013","volume":"50","author":"FM Wachters","year":"2005","unstructured":"Wachters FM, Wong LS, Timens W, Kampinga HH, Groen HJ. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III\/IV NSCLC patients treated with chemotherapy. Lung Cancer. 2005;50(2):211\u20139.","journal-title":"Lung Cancer"},{"key":"3208_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.870302","volume":"13","author":"B Peng","year":"2022","unstructured":"Peng B, Lou H, Chen C, Wang L, Li H, Lu T, et al. Mitochondrial homeostasis\u2013related lncRNAs are potential biomarkers for predicting prognosis and immune response in lung adenocarcinoma. Front Genet. 2022;13:870302.","journal-title":"Front Genet"},{"issue":"11","key":"3208_CR45","doi-asserted-by":"publisher","first-page":"e14124","DOI":"10.1371\/journal.pone.0014124","volume":"5","author":"J Meng","year":"2010","unstructured":"Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, et al. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One. 2010;5(11):e14124.","journal-title":"PLoS One"},{"issue":"6","key":"3208_CR46","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.arbres.2018.11.011","volume":"55","author":"L Muinelo-Romay","year":"2019","unstructured":"Muinelo-Romay L, Garc\u00eda-Gonz\u00e1lez J, Le\u00f3n-Mateos L. Lung cancer and liquid biopsy: realities and challenges in routine clinical practice. Arch Bronconeumol. 2019;55(6):289\u201390.","journal-title":"Arch Bronconeumol"},{"issue":"15","key":"3208_CR47","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1111\/1759-7714.14527","volume":"13","author":"M Omori","year":"2022","unstructured":"Omori M, Noro R, Seike M, Matsuda K, Hirao M, Fukuizumi A, et al. Inhibitors of ABCB1 and ABCG2 overcame resistance in SCLC. Thorac Cancer. 2022;13(15):2142\u201351.","journal-title":"Thorac Cancer"},{"issue":"9","key":"3208_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093233","volume":"21","author":"K Bukowski","year":"2020","unstructured":"Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 2020;21(9):3233.","journal-title":"Int J Mol Sci"},{"issue":"19","key":"3208_CR49","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.3390\/cancers14194562","volume":"14","author":"A Ashrafi","year":"2022","unstructured":"Ashrafi A, Akter Z, Modareszadeh P, Berisha E, Alemi PS, Castro MDC, et al. Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance. Cancers (Basel). 2022;14(19):4562.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"3208_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123729","volume":"12","author":"L Boyero","year":"2020","unstructured":"Boyero L, S\u00e1nchez-Gastaldo A, Alonso M, Noguera-Ucl\u00e9s JF, Molina-Pinelo S, Bernab\u00e9-Caro R. Primary and acquired resistance to immunotherapy in lung cancer: unveiling mechanisms of immune checkpoint blockade therapy. Cancers (Basel). 2020;12(12):3729.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"3208_CR51","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3390\/pharmaceutics15010139","volume":"15","author":"C Gupta","year":"2022","unstructured":"Gupta C, Jaipuria A, Gupta N. Inhalable formulations to treat non-small cell lung cancer (NSCLC): recent therapies and developments. Pharmaceutics. 2022;15(1):139.","journal-title":"Pharmaceutics"},{"issue":"2","key":"3208_CR52","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2217\/fon.14.244","volume":"11","author":"P Pantziarka","year":"2015","unstructured":"Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP. Repurposing drugs in your medicine cabinet: untapped opportunities for cancer therapy? Future Oncol. 2015;11(2):181\u20134.","journal-title":"Future Oncol"},{"issue":"5","key":"3208_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/app15052798","volume":"15","author":"S Herr\u00e1iz-Gil","year":"2025","unstructured":"Herr\u00e1iz-Gil S, Nygren-Jim\u00e9nez E, Acosta-Alonso DN, Le\u00f3n C, Guerrero-Aspizua S. Artificial intelligence-based methods for drug repurposing and development in cancer. Appl Sci. 2025;15(5):2798.","journal-title":"Appl Sci"},{"issue":"3","key":"3208_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032505","volume":"24","author":"GM Casagrande","year":"2023","unstructured":"Casagrande GM, Silva MD, Reis RM, Leal LF. Liquid biopsy for lung cancer: up-to-date and perspectives for screening programs. Int J Mol Sci. 2023;24(3):2505.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3208_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02021-w","volume":"9","author":"L Ma","year":"2024","unstructured":"Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J, et al. Liquid biopsy in cancer: current status, challenges and future prospects. Signal Transduct Target Ther. 2024;9(1):336.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"3208_CR56","doi-asserted-by":"publisher","first-page":"933","DOI":"10.4155\/bio-2018-0006","volume":"10","author":"LM Yee","year":"2018","unstructured":"Yee LM, Lively TG, McShane LM. Biomarkers in early-phase trials: fundamental issues. Bioanalysis. 2018;10(12):933\u201344.","journal-title":"Bioanalysis"},{"issue":"1","key":"3208_CR57","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1021\/acsomega.2c04078","volume":"8","author":"A Sharma","year":"2022","unstructured":"Sharma A, Shambhwani D, Pandey S, Singh J, Lalhlenmawia H, Kumarasamy M, et al. Advances in lung cancer treatment using nanomedicines. ACS Omega. 2022;8(1):10\u201341.","journal-title":"ACS Omega"},{"issue":"7","key":"3208_CR58","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.1007\/s12010-023-04595-7","volume":"196","author":"R Kaur","year":"2024","unstructured":"Kaur R, Suresh PK. Chemoresistance mechanisms in non-small cell lung cancer\u2014opportunities for drug repurposing. Appl Biochem Biotechnol. 2024;196(7):4382\u2013438.","journal-title":"Appl Biochem Biotechnol"},{"key":"3208_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.891652","volume":"12","author":"TB Emran","year":"2022","unstructured":"Emran TB, Shahriar A, Mahmud AR, Rahman T, Abir MH, Siddiquee MF, et al. Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches. Front Oncol. 2022;12:891652.","journal-title":"Front Oncol"},{"issue":"4","key":"3208_CR60","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc1590","volume":"5","author":"M Dean","year":"2005","unstructured":"Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5(4):275\u201384.","journal-title":"Nat Rev Cancer"},{"issue":"6119","key":"3208_CR61","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1126\/science.1227670","volume":"339","author":"A Kreso","year":"2013","unstructured":"Kreso A, O\u2019Brien CA, van Galen P, Gan OI, Notta F, Brown AM, et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science. 2013;339(6119):543\u20138.","journal-title":"Science"},{"key":"3208_CR62","doi-asserted-by":"publisher","first-page":"781425","DOI":"10.3389\/fphar.2021.781425","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang J, Zhou T, Liu Y, Chen S, Yu Z. Application of nanoparticles in the treatment of lung cancer with emphasis on receptors. Front Pharmacol. 2022;12:781425.","journal-title":"Front Pharmacol"},{"key":"3208_CR63","doi-asserted-by":"publisher","first-page":"1363346","DOI":"10.3389\/fphar.2024.1363346","volume":"15","author":"J Zhang","year":"2024","unstructured":"Zhang J, Li Y, Guo S, Zhang W, Fang B, Wang S. Moving beyond traditional therapies: the role of nanomedicines in lung cancer. Front Pharmacol. 2024;15:1363346.","journal-title":"Front Pharmacol"},{"issue":"6","key":"3208_CR64","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10989-025-10767-2","volume":"31","author":"D Karati","year":"2025","unstructured":"Karati D, Das S, Mitra S. Peptide-based drugs: emerging treatment strategies of lung cancer by overcoming chemoresistance. Int J Pept Res Ther. 2025;31(6):103.","journal-title":"Int J Pept Res Ther"},{"issue":"5","key":"3208_CR65","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1007\/s00210-023-02838-2","volume":"397","author":"D Karati","year":"2024","unstructured":"Karati D, Mukherjee S, Roy S. Deciphering the molecular mechanistic paths describing the chemotherapeutic potential and epigenetic regulation of curcumin in lung cancer: a mini review. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(5):2715\u201325.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"3208_CR66","doi-asserted-by":"publisher","first-page":"e18761429273223","DOI":"10.2174\/0118761429273223231124072223","volume":"17","author":"D Karati","year":"2024","unstructured":"Karati D, Kumar D. Molecular insight into the apoptotic mechanism of cancer cells: an explicative review. Curr Mol Pharmacol. 2024;17(1):e18761429273223.","journal-title":"Curr Mol Pharmacol"},{"issue":"7","key":"3208_CR67","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s12032-025-02818-x","volume":"42","author":"A Sinha","year":"2025","unstructured":"Sinha A, Ghosh D, Karati D. Tumor microenvironment and immunotherapy: from bench to bedside. Med Oncol. 2025;42(7):244.","journal-title":"Med Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03208-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03208-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03208-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T16:04:50Z","timestamp":1770393890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03208-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":67,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["3208"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03208-z","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Since this article is a narrative review and the article does not entail direct work with human participants, animal subjects and clinical samples, ethical approval was unnecessary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"100"}}